| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/09/2011 | CA2558199C Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
| 08/09/2011 | CA2552050C Substituted heterocycles and the uses thereof |
| 08/09/2011 | CA2551508C Novel quinoline derivatives |
| 08/09/2011 | CA2542279C Bicyclic [3.1.0] derivatives as glycine transporter inhibitors |
| 08/09/2011 | CA2540768C Pyrazolo and imidazo-pyrimidine derivatives |
| 08/09/2011 | CA2539707C Quinoline potassium channel inhibitors |
| 08/09/2011 | CA2537092C Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| 08/09/2011 | CA2529507C Compounds and methods for inducing apoptosis in cancer cells |
| 08/09/2011 | CA2526943C Compositions comprising hepoxilin analogs and their use in the treatment of cancer |
| 08/09/2011 | CA2520027C 2,3,6-trisubstituted-4-pyrimidone derivatives |
| 08/09/2011 | CA2518918C Alpha-hydroxy acid ester drug delivery compositions and methods of use |
| 08/09/2011 | CA2514227C Combination therapy of zd6474 with 5-fu or/and cpt-11 |
| 08/09/2011 | CA2512000C Selective estrogen receptor modulator |
| 08/09/2011 | CA2500712C Antibiotic pharmaceutical composition with improved oral absorbability |
| 08/09/2011 | CA2494088C Echinacea angustifolia extracts |
| 08/09/2011 | CA2487727C Compounds useful in the treatment of anthrax and inhibiting lethal factor |
| 08/09/2011 | CA2487297C The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases |
| 08/09/2011 | CA2483786C Preparations for the topical application of anti-androgenically active substances |
| 08/09/2011 | CA2468811C Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders |
| 08/09/2011 | CA2468419C Disinfectant solutions consisting essentially of a tetrasodium edta salt and a solvent and use thereof for disinfection |
| 08/09/2011 | CA2465813C Processed baby food with unsaturated fatty acids and/or nucleotides |
| 08/09/2011 | CA2464468C Gentle-acting skin-disinfectants and hydroalcoholic gel formulations |
| 08/09/2011 | CA2463938C Polymer conjugates of opioid antagonists |
| 08/09/2011 | CA2461951C Process for producing pravastatin sodium salt using streptomyces flavidovirens dsm 14455 |
| 08/09/2011 | CA2459887C Carba-sugar amine derivative and glycolipid metabolic disorder treating agent containing the same as active ingredient |
| 08/09/2011 | CA2451377C Oral pharmaceutical compositions with improved bioavailability |
| 08/09/2011 | CA2451151C Carbamates of 2-heterocyclic-1,2-ethanediols |
| 08/09/2011 | CA2448927C Pharmaceutical composition |
| 08/09/2011 | CA2447921C Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 08/09/2011 | CA2445651C Cathartic composition comprising halogenated prostaglandin derivatives |
| 08/09/2011 | CA2445190C Indole, azaindole and related heterocyclic amidopiperazine derivatives |
| 08/09/2011 | CA2441534C Benzoaxathiepin derivatives and their use as medicines |
| 08/09/2011 | CA2441492C Rho-kinase inhibitors |
| 08/09/2011 | CA2439288C Method for protecting cells and tissues from ionizing radiation toxicity with .alpha.,.beta. unsaturated aryl sulfones |
| 08/09/2011 | CA2438595C Glucopyranosyloxypyrazole derivatives and medicinal use thereof |
| 08/09/2011 | CA2438092C Ttk in diagnosis and as a therapeutic target in cancer |
| 08/09/2011 | CA2434484C Compositions comprising ibuprofen and diphenhydramine to treat pain-associated sleep disturbances |
| 08/09/2011 | CA2432568C Benzoylpyridazines |
| 08/09/2011 | CA2431083C Inflammatory cytokine release inhibitor |
| 08/09/2011 | CA2428039C Serotonergic agents |
| 08/09/2011 | CA2422589C Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations |
| 08/09/2011 | CA2407415C Chondroitin synthase gene and methods of making and using same |
| 08/09/2011 | CA2405958C Hybrid glycosylated products and their production and use |
| 08/09/2011 | CA2370738C Uteroglobin in the treatment of iga mediated autoimmune disorders |
| 08/09/2011 | CA2366462C Two-step immunization procedure against chlamydia infection |
| 08/09/2011 | CA2293415C Compositions for treating and preventing arterial thrombosis and use of a factor xa inhibitor on its own and/or combined with a platelet antiaggregating agent |
| 08/09/2011 | CA2253240C Hereditary hemochromatosis gene |
| 08/09/2011 | CA2243559C Pharmaceutical composition for immunomodulation |
| 08/09/2011 | CA2237995C Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them |
| 08/09/2011 | CA2205075C Reagent and method for inhibition of n-ras expression |
| 08/05/2011 | DE202006020979U1 Stabiles mikronisiertes Candesartan-Cilexetil Stable micronized candesartan cilexetil |
| 08/04/2011 | WO2011094749A2 Small molecule inhibitors that block assembly of the tgf-beta signaling complex |
| 08/04/2011 | WO2011094722A1 Use of tyrosine kinase inhibitors for treatment of cushing's disease and hypercortisolism |
| 08/04/2011 | WO2011094708A2 Small molecules for the modulation of mcl-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders |
| 08/04/2011 | WO2011094671A2 N-terminally conjugated polypeptides for targeted therapy and diagnosis |
| 08/04/2011 | WO2011094657A2 Additives for chlorine dioxide-containing compositions |
| 08/04/2011 | WO2011094628A1 Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases |
| 08/04/2011 | WO2011094598A2 Compositions and methods for reversing corticosteroid resistance or treating respiratory infections |
| 08/04/2011 | WO2011094589A1 Nonsteroidal antiinflammatory derivatives with decreased toxicity and methods of use |
| 08/04/2011 | WO2011094565A1 Formulations of bendamustine |
| 08/04/2011 | WO2011094560A1 Ph responsive fluorescent false neurotransmitters and their use |
| 08/04/2011 | WO2011094557A1 Nutritional emulsions comprising calcium hmb |
| 08/04/2011 | WO2011094549A1 Nutritional powders comprising spray dried hmb |
| 08/04/2011 | WO2011094545A2 Compositions and methods for enhancing proteasome activity |
| 08/04/2011 | WO2011094544A1 Nutritional emulsions comprising calcium hmb and soluble protein |
| 08/04/2011 | WO2011094496A2 Trypsin-like serine protease inhibitors, and their preparation and use |
| 08/04/2011 | WO2011094491A1 Compositions comprising sugar-cysteine products |
| 08/04/2011 | WO2011094490A1 Methods of preparing thiazolidines |
| 08/04/2011 | WO2011094489A1 Therapies for treating hepatitis c virus infection |
| 08/04/2011 | WO2011094450A1 Boron-containing small molecules |
| 08/04/2011 | WO2011094434A2 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof |
| 08/04/2011 | WO2011094431A1 Sustained-release nsaid/hmg coa reductase inhibitor compositions |
| 08/04/2011 | WO2011094389A2 Cxcr4 antagonists for imaging of cancer and inflammatory disorders |
| 08/04/2011 | WO2011094352A1 In-vivo non-viral gene delivery of human vascular endothelial growth factor following islet transplantation |
| 08/04/2011 | WO2011094335A2 Microrna signatures predicting responsiveness to anti-her2 therapy |
| 08/04/2011 | WO2011094290A1 Pyrazolopyrimidine kinase inhibitors |
| 08/04/2011 | WO2011094288A1 Pyrazolopyrazine kinase inhibitors |
| 08/04/2011 | WO2011094285A1 Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization |
| 08/04/2011 | WO2011094283A1 Pyrazolopyridine kinase inhibitors |
| 08/04/2011 | WO2011094273A1 Pyrazolopyridine kinase inhibitors |
| 08/04/2011 | WO2011094260A2 Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer |
| 08/04/2011 | WO2011094231A1 Therapeutic agents for treatment of ocular hypertension |
| 08/04/2011 | WO2011094225A1 Therapeutically active cyclopentanes |
| 08/04/2011 | WO2011094209A1 Pharmaceutical compositions for the treatment of pain and other indicatons |
| 08/04/2011 | WO2011094208A2 Methods and pharmaceutical compositions for preventing and treating renal impairment |
| 08/04/2011 | WO2011094016A1 Compounds, compositions and methods for preventing skin darkening |
| 08/04/2011 | WO2011094008A1 Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| 08/04/2011 | WO2011093924A1 Bicyclic heteroaryl inhibitors of pde4 |
| 08/04/2011 | WO2011093851A1 Method for treatment of vascular hyperpermeability |
| 08/04/2011 | WO2011093833A2 Effervescent formulations comprising second generation cephalosporin |
| 08/04/2011 | WO2011093832A2 Stable efervescent formulations comprising cefaclor |
| 08/04/2011 | WO2011093829A1 Effervescent formulations comprising cefixime and clavulanic acid as active agents |
| 08/04/2011 | WO2011093827A1 Water dispersible cefdinir and clavulanic acid formulations for treatment of bacterial infections |
| 08/04/2011 | WO2011093826A2 Effervescent formulations comprising cefaclor and clavulanic acid as active agents |
| 08/04/2011 | WO2011093823A2 Effervescent formulations comprising cefaclor and clavulanic acid |
| 08/04/2011 | WO2011093822A1 Effervescent formulations comprising cefixime and clavulanic acid as active agents |
| 08/04/2011 | WO2011093821A1 Effervescent formulations comprising cefdinir and clavulanic acid |
| 08/04/2011 | WO2011093819A2 New combination comprising tiotropium |
| 08/04/2011 | WO2011093818A2 Pharmaceutical compositions comprising salmeterol and fluticasone |
| 08/04/2011 | WO2011093817A1 Pharmaceutical compositions comprising tiotropium, formoterol and budesonide |